Literature DB >> 21191667

Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma.

Daniel P Lindholm1, Barbro Eriksson, Dan Granberg.   

Abstract

Poorly differentiated endocrine carcinomas (PDEC) are usually treated with cisplatin-based chemotherapy regimens. We here present a case with a dramatic response (both radiologically and biochemically) to the combination of temozolomide and bevacizumab, after failure of cisplatin and etoposide, with continued tumor shrinkage at 5 months. Temozolomide combined with bevacizumab might be a good treatment option in PDEC, perhaps even in a first-line setting. Prospective studies to answer this are warranted.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21191667     DOI： 10.1007/s12032-010-9789-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  9 in total

1.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

Authors:  M R Middleton; J J Grob; N Aaronson; G Fierlbeck; W Tilgen; S Seiter; M Gore; S Aamdal; J Cebon; A Coates; B Dreno; M Henz; D Schadendorf; A Kapp; J Weiss; U Fraass; P Statkevich; M Muller; N Thatcher
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

2.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Authors:  L G Presta; H Chen; S J O'Connor; V Chisholm; Y G Meng; L Krummen; M Winkler; N Ferrara
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

3.  Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.

Authors:  M L Fjällskog; D P Granberg; S L Welin; C Eriksson; K E Oberg; E T Janson; B K Eriksson
Journal:  Cancer       Date:  2001-09-01       Impact factor: 6.860

4.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

5.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

7.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

8.  O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

Authors:  Matthew H Kulke; Jason L Hornick; Christine Frauenhoffer; Susanne Hooshmand; David P Ryan; Peter C Enzinger; Jeffrey A Meyerhardt; Jeffrey W Clark; Keith Stuart; Charles S Fuchs; Mark S Redston
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

9.  Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Authors:  Sara Ekeblad; Anders Sundin; Eva Tiensuu Janson; Staffan Welin; Dan Granberg; Henrik Kindmark; Kristina Dunder; Gordana Kozlovacki; Håkan Orlefors; Mattias Sigurd; Kjell Oberg; Barbro Eriksson; Britt Skogseid
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531
  9 in total
  3 in total

1.  A multimodal approach to the management of neuroendocrine tumour liver metastases.

Authors:  Ron Basuroy; Rajaventhan Srirajaskanthan; John K Ramage
Journal:  Int J Hepatol       Date:  2012-02-15

2.  Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report.

Authors:  Maroun Bou Zerdan; Ramzi Hamouche; Youssef Bouferraa; Camil Chouairy; Dany Gholam
Journal:  SAGE Open Med Case Rep       Date:  2022-06-24

3.  Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.

Authors:  C De Divitiis; C von Arx; A M Grimaldi; D Cicala; F Tatangelo; A Arcella; G M Romano; E Simeone; R V Iaffaioli; P A Ascierto; S Tafuto
Journal:  J Transl Med       Date:  2016-05-03       Impact factor: 5.531
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.